Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.

http://www.wikidata.org/entity/Q37437235

about

The associations between five polymorphisms of vascular endothelial growth factor and renal cell carcinoma risk: an updated meta-analysis.PharmGKB summary: pazopanib pathway, pharmacokinetics.Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing Surgery for metastatic tumors of the pancreas Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis.

P2860

Q37722501-EC4F3BF9-E264-4AF4-BD3C-F061F83227BC Q38693146-C6B97A1C-4419-451B-B256-16EC3120F5EA Q38968504-FDAE9125-FDD4-47C5-A497-109DEC2AA4F0 Q42141719-40B18255-EB5A-46F8-95E4-146D2C7B16DF Q47101376-7C92A57F-4F8A-4F50-BEA4-B6D835EC7A4F Q53634559-AECF4BC2-E548-4563-8FA4-7DD4BE279B86

P2860

Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.

http://www.wikidata.org/entity/Q37437235

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Angiogenesis genotyping in the ...... advanced renal cell carcinoma.

@en

Angiogenesis genotyping in the ...... advanced renal cell carcinoma.

@nl

type

label

Angiogenesis genotyping in the ...... advanced renal cell carcinoma.

@en

Angiogenesis genotyping in the ...... advanced renal cell carcinoma.

@nl

prefLabel

Angiogenesis genotyping in the ...... advanced renal cell carcinoma.

@en

Angiogenesis genotyping in the ...... advanced renal cell carcinoma.

@nl

P1433

Q37437235-3276073E-4150-4231-82C6-CFD2F1C93271

P1476

Q37437235-78602B09-5597-4651-9CF6-82723C01E972

P2093

Q37437235-0216F9E2-CD2B-4877-B548-A38AD842429E

Q37437235-2EE75600-1569-405F-AB33-634AD48D7E3D

Q37437235-3B2E978E-E909-455E-A917-4654662FC422

Q37437235-4022C341-F4E2-44AD-9600-9D3F4410E03E

Q37437235-57DFC314-E60F-426F-AF0D-1BC06ADB9FB6

Q37437235-89142764-2C2E-4522-861F-86C92168B4ED

Q37437235-A9D32AA6-0B44-48DC-A9A0-D8675FBEA3E5

Q37437235-EFFDE7DF-5B3B-469A-A872-96DF4BAA3AE1

P2860

Q37437235-0A79C1FF-0007-48E1-AF9D-196A8C8CDA40

Q37437235-0AD09856-4D98-4275-8A74-E85F7BAB7FFA

Q37437235-19E7144E-DCCA-45EC-9D3C-F36EFFF3A878

Q37437235-2556EFB1-B911-4BF8-A127-8505C20B4AC9

Q37437235-28DBCE97-F42A-4B9B-B6C4-3EC5CE2A94BA

Q37437235-28E1C0B8-635B-4951-B304-A1E54C97E332

Q37437235-2D5C5B2A-F05A-48C4-A305-79DF3C209C6C

Q37437235-3B0869EB-5004-4D52-8E8D-9EA46FCAC326

Q37437235-6015EC30-3D34-4D10-8F46-C15F51ABDA72

Q37437235-646F451E-A57E-4416-A85C-DF8DCCCC32AD

P304

Q37437235-41FFFD72-4AF5-4559-8896-769BDE896E1F

P31

Q37437235-0098836D-B035-4D75-99CD-5C5EC2074593

P356

Q37437235-C409B414-429F-4D6E-B941-B77276D930B5

P407

Q37437235-1EB618CA-8435-4935-91CD-F0C74074B637

P433

Q37437235-D87F60F9-4943-4CCE-BD74-689577FF8A4B

P478

Q37437235-F2963893-51F0-4CC6-B799-B88AA844F31D

P50

Q37437235-0F7F65EF-024B-4133-9C7B-97658FB4370D

Q37437235-1055B59C-7A12-4301-847A-E9A2EC9CB387

Q37437235-295D7F21-329F-4B43-8759-3AAD340E08A1

Q37437235-DF7BDEAF-4724-44A4-8DBB-A2872284CC31

P577

Q37437235-F14C18E4-366B-4B5E-886D-8B4021636986

P698

Q37437235-6DDA2782-AF93-4931-8234-496DFCE0BC17

P921

Q37437235-40D3900A-9428-4CAF-92CF-ECC1F552895D

P932

Q37437235-DCF7DAE2-4A0F-4D27-8DB0-4399DD9C7E31

P356

ONCOTARGET.9229

P1433

P1476

Angiogenesis genotyping in the ...... advanced renal cell carcinoma

@en

P2093

Alessandro Bittoni

http://www.w3.org/2001/XMLSchema#string

Kalliopi Andrikou

http://www.w3.org/2001/XMLSchema#string

Luciano Burattini

http://www.w3.org/2001/XMLSchema#string

Mario Scartozzi

http://www.w3.org/2001/XMLSchema#string

Maristella Bianconi

http://www.w3.org/2001/XMLSchema#string

Michela Del Prete

http://www.w3.org/2001/XMLSchema#string

Riccardo Giampieri

http://www.w3.org/2001/XMLSchema#string

Rodolfo Montironi

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.

Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

Identification of cis- and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels.

Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.

Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS

VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.

P304

37599-37607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.9229

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Stefano Cascinu

Cristian Loretelli

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27175586

http://www.w3.org/2001/XMLSchema#string

P921

P932

5122335

http://www.w3.org/2001/XMLSchema#string